If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Biphasic Insulin Aspart 30 Shows Superiority to Insulin Glargine for Type 2 Diabetes Inadequately Controlled With Oral Drugs: Presented at EASD By Bruce Sylvester VIENNA, Austria -- October 6, 2009 -- Treatment of inadequately controlled type 2 diabetes with once daily biphasic insulin aspart 30 (BIAsp 30) in combination with metformin and glimepiride, results in significantly higher reductions in both haemoglobin (Hb) A1C and postprandial hyperglycaemia, compared with patients receiving insulin glargine plus metformin and glimepiride. “We found that biphasic insulin aspart 30 was associated with significantly lower post-dinner and bedtime blood glucose levels,” said presenter and lead investigator Edward Franek, MD, Clinic of Internal Diseases, Central Clinical Hospital, Warsaw, Poland, on October 2 at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD). Dr. Franek noted that the purpose of the 26-week, open-label, randomised, parallel-group study was to compare the efficacy and safety of BIAsp 30 with insulin glargine, both administered once daily to insulin-naïve subjects with type 2 diabetes who had been inadequately controlled with 2 oral antidiabetic drugs. Patients were randomised to receive BIAsp 30 0.18 U/kg before dinner or insulin glargine 0.18 U/kg at bedtime, both in combination with metformin and glimepiride. At 26 weeks, treatment dose had increased to 0.32 U/kg with BIAsp 30 and 0.29 U/Kg with insulin glargine. A total of 433 patients completed the study. Results showed a mean reduction in Hb A1C from baseline of -1.41% with BIAsp 30 and -1.25% with insulin glargine (P = .029). Hb A1C levels after dinner were significantly lower with BIAsp 30 than glargine (P = .04). Similar results were also observed at bedtime for patients receiving BIAsp 30 compared with glargine insulin (P < .01). There were 3 major hypoglycaemic episodes in the BIAsp 30 group and 2 in the insulin glargine group. The relative risk of experiencing a nocturnal hypoglycaemic episode was significantly higher among patients treated with BIAsp 30 than insulin glargine (P = .003). Dr. Franek said that the reason for this difference remains unclear, and noted that the absolute rates of such episodes were low for both treatment groups. Funding for this study was provided by Novo Nordisk. [Presentation title: Once Daily Initiation With Biphasic Insulin Aspart 30 (BIAsp 30) Versus Insulin Glargine in Patients With Type 2 Diabetes Inadequately Controlled With Oral Drugs - a Randomized Controlled Trial. Abstract 213]
|
